Jasper Therapeutics Inc (JSPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) has a cash flow conversion efficiency ratio of -1.469x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.00 Million) by net assets ($11.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jasper Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Jasper Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Jasper Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Jasper Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jasper Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
A SPAC III Acquisition Corp. Class A Ordinary Shares
NASDAQ:ASPC
|
-0.056x |
|
Origin Materials Inc
NASDAQ:ORGN
|
-0.028x |
|
Getin Holding SA
WAR:GTN
|
0.068x |
|
Venteny Fortuna International
JK:VTNY
|
-0.027x |
|
Avante Logixx Inc
V:XX
|
0.033x |
|
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B
SHG:900904
|
0.050x |
|
Hitech Corporation Limited
NSE:HITECHCORP
|
0.093x |
|
Bayfirst Financial Corp
NASDAQ:BAFN
|
0.540x |
Annual Cash Flow Conversion Efficiency for Jasper Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Jasper Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see JSPR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $61.67 Million | $-62.60 Million | -1.015x | -52.92% |
| 2023-12-31 | $78.44 Million | $-52.07 Million | -0.664x | +47.91% |
| 2022-12-31 | $35.99 Million | $-45.86 Million | -1.274x | -163.02% |
| 2021-12-31 | $69.52 Million | $-33.68 Million | -0.484x | -193.17% |
| 2020-12-31 | $-35.13 Million | $-18.27 Million | 0.520x | +657.27% |
| 2019-12-31 | $21.10 Million | $-1.97 Million | -0.093x | -- |
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercializ… Read more